Patent ID: 11873491
Assignee: ALNYLAM PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5,
wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region 15-30 nucleotide pairs in length,
wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from nucleotides 769-821 of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the corresponding nucleotide sequence of SEQ ID NO:5,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a nucleotide modification.